Cassava Sciences Inc vs Under Armour Inc Class A — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 52.5× Cassava Sciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Under Armour Inc Class A for 18 Days on average.
| FLNA | UA | |
|---|---|---|
Market Cap | $39.40M | $2.07B |
Volume | 759,018 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $7.88 |
52-Week Low | $0.68 | $3.96 |
Typical Hold Time | 37 Days | 18 Days |
Enterprise Value | -$43.28M | $3.05B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Under Armour (UA) trades at $4.70, down 0.42% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company faces significant fundamental challenges with declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability metrics, including a -9.99% net income margin and -29.82% ROE. Recent earnings show volatility with two beats and one miss in the last four quarters, while cash flow remains negative across all categories.
The outlook remains challenging with declining revenue trends and persistent profitability issues offset by relatively low valuation multiples. Investment opportunity exists if management can stabilize sales and improve margins, but risks include continued consumer demand weakness and competitive pressures in the athletic apparel sector. Analyst sentiment is mixed with 41% buy ratings but growing concerns about the company's turnaround prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →